HRS-6093 / Jiangsu Hengrui Pharma - LARVOL DELTA

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations (clinicaltrials.gov) - P1 | N=153 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor • KRAS

HENGRUI PHARMA's Anti-tumor Drug HRS-6093 Receives Approval from CN for Clinical Trials (iis.aastocks.com) - "The clinical trials are set to commence in the near future."

New trial • Oncology • Solid Tumor

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations (clinicaltrials.gov) - P1 | N=153 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Solid Tumor • KRAS